Bristol-Myers Squibb (NYSE:BMY) Stock Position Reduced by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC decreased its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.6% in the third quarter, Holdings Channel reports. The institutional investor owned 12,081 shares of the biopharmaceutical company’s stock after selling 987 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Bristol-Myers Squibb were worth $641,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of BMY. ESL Trust Services LLC purchased a new stake in shares of Bristol-Myers Squibb during the first quarter worth $27,000. ORG Wealth Partners LLC purchased a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth about $34,000. LGT Financial Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 42.7% during the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 227 shares during the last quarter. MFA Wealth Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at approximately $39,000. Finally, Beach Investment Counsel Inc. PA bought a new position in Bristol-Myers Squibb during the second quarter valued at approximately $42,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.3 %

NYSE BMY opened at $52.68 on Thursday. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $55.03. The stock has a market cap of $106.79 billion, a PE ratio of -16.99, a PEG ratio of 13.75 and a beta of 0.46. The firm has a 50-day simple moving average of $50.98 and a 200 day simple moving average of $46.48. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.56%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s payout ratio is presently -77.42%.

Wall Street Analysts Forecast Growth

BMY has been the subject of several recent research reports. TD Cowen boosted their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. UBS Group increased their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 9th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $48.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, September 23rd. Jefferies Financial Group raised their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research note on Wednesday, August 28th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $52.38.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.